UNITEFA, CONICET and Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba X5000HUA, Argentina.
Instituto de Investigación Médica Mercedes y Martín Ferreyra, Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad Nacional de Córdoba (INIMEC-CONICET-UNC), Córdoba X5000HUA, Argentina.
Mol Pharm. 2021 Mar 1;18(3):807-821. doi: 10.1021/acs.molpharmaceut.0c00692. Epub 2020 Dec 24.
Nanotechnology is a very promising technological tool to combat health problems associated with the loss of effectiveness of currently used antibiotics. Previously, we developed a formulation consisting of a chitosan and tween 80-decorated alginate nanocarrier that encapsulates rifampicin and the antioxidant ascorbic acid (RIF/ASC), intended for the treatment of respiratory intracellular infections. Here, we investigated the effects of RIF/ASC-loaded NPs on the respiratory mucus and the pulmonary surfactant. In addition, we evaluated their cytotoxicity for lung cells , and their biodistribution on rat lungs after their intratracheal administration. Findings herein demonstrated that RIF/ASC-loaded NPs display a favorable lung biocompatibility profile and a uniform distribution throughout lung lobules. RIF/ASC-loaded NPs were mainly uptaken by lung macrophages, their primary target. In summary, findings show that our novel designed RIF/ASC NPs could be a suitable system for antibiotic lung administration with promising perspectives for the treatment of pulmonary intracellular infections.
纳米技术是一种非常有前途的技术工具，可以用来解决与目前使用的抗生素效果降低相关的健康问题。此前，我们开发了一种由壳聚糖和聚山梨酯 80 修饰的海藻酸钠纳米载体组成的制剂，该制剂包封了利福平（RIF）和抗氧化剂抗坏血酸（ASC），用于治疗呼吸道细胞内感染。在这里，我们研究了载 RIF/ASC 的 NPs 对呼吸道粘液和肺表面活性剂的影响。此外，我们评估了它们对肺细胞的细胞毒性，以及它们经气管内给药后在大鼠肺部的生物分布。研究结果表明，载 RIF/ASC 的 NPs 具有良好的肺生物相容性和在整个肺小叶中的均匀分布。载 RIF/ASC 的 NPs 主要被肺巨噬细胞摄取，肺巨噬细胞是它们的主要靶细胞。总之，研究结果表明，我们设计的新型 RIF/ASC NPs 可能是一种适合肺部抗生素给药的系统，为治疗肺部细胞内感染提供了有前景的治疗方法。
